Bicifadine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Jytdog (talk | contribs) at 13:30, 15 July 2015 (update). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Bicifadine
Clinical data
Routes of
administration		oral
ATC code
  • none
Legal status
Legal status
  • US: Unscheduled
Pharmacokinetic data
Elimination half-life1.6 hours
Excretionrenal
Identifiers
  • 1-(4-Methylphenyl)-3-azabicyclo[3.1.0]hexane
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
ECHA InfoCard100.124.957 Edit this at Wikidata
Chemical and physical data
FormulaC12H15N
Molar mass173.25 g/mol g·mol−1
3D model (JSmol)
  • c1cc(ccc1C)[C@]32CNC[C@@H]2C3
  • InChI=1S/C12H15N/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12/h2-5,11,13H,6-8H2,1H3/t11-,12+/m0/s1 checkY
  • Key:OFYVIGTWSQPCLF-NWDGAFQWSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth.[1][2][3]

In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a Phase III clinical trial for chronic lower back pain.[4][5][6] XTL ran a PhaseIIb clinical trial for pain caused by diabetic neuropathy, which failed in 2008;[7] XTL terminated the agreement in 2010.[8] In 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio.[9]

Bicifadine has a non-opioid, non-NSAID mechanism for the treatment of pain, which should have less abuse potential than opioid drugs and less propensity to cause gastric ulcers than NSAID drugs.[10] While the drug is purported to be a serotonin (SERT) and noradrenaline transporter (NET) inhibitor, it also has effects at the dopamine transporter (DAT), effectively making it a broad-spectrum monoamine transporter inhibitor or "triple reuptake inhibitor."[11]

See also

References

  1. ^ Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig. 2008 Sep;5(3):142-7. PMID 20046357 PMC2796030
  2. ^ [http://www.sec.gov/Archives/edgar/data/1066833/000114420404018172/v08017_ex10-51.txt SEC Filing: Wyeth-DOV Restated License Agreement Page accessed July 15, 2015]
  3. ^ Neubauer, DN. "Indiplon". pp 453-464 in GABA and Sleep: Molecular, Functional and Clinical Aspects. Eds Jaime M. Monti, Seithikurippu Ratnas Pandi-Perumal, Hanns Möhler. Springer Science & Business Media, 2010 ISBN 9783034602266
  4. ^ BioCentury, July 26, 2010 [full citation needed]
  5. ^ "Euthymics: Balancing act" (PDF). BioCentury, The Bernstein Report on Biobusiness. December 5, 2011. p. A13.
  6. ^ John Caroll for Fierce Biotech. Jan 07, 2007 XTL licenses development rights to pain therapy
  7. ^ Fierce Biotech. December 9, 2008 Tiny XTL cuts costs, jobs
  8. ^ XTL Form 6-K March, 2013
  9. ^ Fierce Biotech July 22, 2010 Euthymics lands $24M to fund antidepressant work
  10. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 7096604, please use {{cite journal}} with |pmid=7096604 instead.
  11. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 17325229, please use {{cite journal}} with |pmid=17325229 instead.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Bicifadine&oldid=671557868"